ArticleF&S reports2025
Attrition rates of in vitro fertilization in patients with male factor infertility using testicular sperm.
Article in F&S reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the oocyte to blastocyst attrition rate in patients undergoing in vitro fertilization (IVF) with male factor infertility (MFI) using testicular sperm. Design: Retrospective cohort study. Subjects: Patients who underwent IVF using testicular sperm for MFI between January 1, 2017, and March 23, 2023. Intervention: Testicular sperm extraction (TESE) with intracytoplasmic sperm injection. Main Outcome Measures: The fertilization and blastulation outcomes. Results: A total of 120 IVF cycles using testicular sperm were identified. For comparison, 122 IVF cycles in patients with unexplained infertility who had normal semen analysis and used ejaculated sperm for intracytoplasmic sperm injection were reviewed as a control group. Testicular sperm cycles were further grouped by prognosis on the basis of the indication for TESE: good prognosis (n = 42, obstructive azoospermia); moderate prognosis (n = 67, increased deoxyribonucleic acid fragmentation, prior failed IVF, and recurrent pregnancy loss); and poor prognosis (n = 11, cryptozoospermia or nonobstructive azoospermia). Female baseline characteristics were similar among the groups except for body mass index. The fertilization rate was lower in all TESE groups than in the control group; however, no differences in fertilization rates were noted within the TESE groups (good vs. moderate vs. poor). The blastulation rates were similar between the good-prognosis TESE and control groups. However, the moderate- and poor-prognosis TESE groups had lower blastulation rates than the control group. Conclusion: This model may help practitioners counsel patients with MFI using testicular sperm to appropriately set expectations for blastocyst outcomes on the basis of the diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.